Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY)

Market Closed
15 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
38. 92
-1.59
-3.92%
Pre Market
$
40. 00
+1.08 +2.77%
2.05B Market Cap
13.86 P/E Ratio
0% Div Yield
1,058,697 Volume
3.01 Eps
$ 40.51
Previous Close
Day Range
38.75 40.87
Year Range
25.52 40.93
Want to track HRMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 70 days
HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money

HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Accesswire | 1 year ago
Harmony Biosciences Holdings, Inc. (HRMY) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

Harmony Biosciences Holdings, Inc. (HRMY) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Accesswire | 1 year ago
Harmony Biosciences (HRMY) Surges 6.7%: Is This an Indication of Further Gains?

Harmony Biosciences (HRMY) Surges 6.7%: Is This an Indication of Further Gains?

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks | 1 year ago
Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.

Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Accesswire | 1 year ago
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses.

An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses.

NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Accesswire | 1 year ago
Harmony Biosciences (HRMY) Upgraded to Buy: Here's What You Should Know

Harmony Biosciences (HRMY) Upgraded to Buy: Here's What You Should Know

Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 year ago
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

HRMY vs. REGN: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 1 year ago
Shareholder Rights Advocates at Levi & Korsinsky Investigate Harmony Biosciences Holdings, Inc. (HRMY) Regarding Possible Securities Fraud Violations

Shareholder Rights Advocates at Levi & Korsinsky Investigate Harmony Biosciences Holdings, Inc. (HRMY) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Accesswire | 1 year ago
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says

Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says

UBS initiated coverage on Harmony Biosciences Holdings Inc HRMY, a commercial-stage biopharmaceutical company focused on rare neurological disorders.

Benzinga | 1 year ago
HRMY or REGN: Which Is the Better Value Stock Right Now?

HRMY or REGN: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks | 1 year ago
Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?

Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
Loading...
Load More